Compare VIOT & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIOT | KPTI |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.6M | 148.0M |
| IPO Year | 2018 | 2013 |
| Metric | VIOT | KPTI |
|---|---|---|
| Price | $1.42 | $6.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $22.17 |
| AVG Volume (30 Days) | 345.7K | ★ 431.6K |
| Earning Date | 03-24-2026 | 02-12-2026 |
| Dividend Yield | ★ 5.50% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $385,267,177.00 | $142,530,000.00 |
| Revenue This Year | $42.19 | $3.55 |
| Revenue Next Year | $0.96 | N/A |
| P/E Ratio | $3.53 | ★ N/A |
| Revenue Growth | ★ 16.89 | N/A |
| 52 Week Low | $1.18 | $3.51 |
| 52 Week High | $4.33 | $10.38 |
| Indicator | VIOT | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 41.09 | 43.37 |
| Support Level | $1.30 | $6.22 |
| Resistance Level | $1.42 | $6.97 |
| Average True Range (ATR) | 0.09 | 0.57 |
| MACD | 0.04 | -0.07 |
| Stochastic Oscillator | 93.10 | 29.06 |
Viomi Technology Co Ltd, along with its subsidiaries, specializes in the development and sale of Internet-of-Things-enabled smart home products, particularly focusing on home water solutions. The company markets its products in China and generates the majority of its revenue through the sale of smart water purification systems and other connected home devices designed to improve convenience and automation in residential settings. Its product offerings include water purification products, water heaters, smart water kettles, electric kettles, water filters, range hoods, gas stoves, and other small appliances.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.